Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Diabetic Kidney Disease: The CREDENCE Trial. Januzzi JL, Mohebi R, Liu Y, Sattar N, et al. Circulation 2023;148:651-660.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Januzzi JL, Mohebi R, Liu Y, Sattar N, et al. Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Diabetic Kidney Disease: The CREDENCE Trial. Circulation 2023;148:651-660.
PMID: 37603600